Gastroesophageal Reflux Disease Therapeutics Market (2026 - 2033)

Gastroesophageal Reflux Disease Therapeutics Market Summary

The global gastroesophageal reflux disease therapeutics market size was valued at USD 5.2 billion in 2025 and is projected to grow from USD 5.3 billion in 2026 to USD 6.1 billion by 2033, growing at a CAGR of 2.0% from 2026 to 2033. North America dominated the market with the largest revenue share of 38.1% in 2025. Lifestyle changes, including urbanization and dietary habits, further contribute to the rising prevalence of GERD.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

A 2024 BMC study conducted in Iran reported a 10.99% prevalence rate, pointing to lifestyle factors such as high sugar intake and low physical activity as significant triggers. Moreover, 45.3% of participants engaged in insufficient physical activity, underscoring the correlation between sedentary lifestyles, processed food consumption, and increased GERD symptoms. These trends necessitate effective therapeutic interventions to manage the growing patient population. The rising prevalence of gastroesophageal reflux disease (GERD) significantly drives the therapeutics market, with approximately 13.98% of the adult population globally affected by this condition. Notably, regional variations influence demand, with prevalence rates soaring to 22.40% in Turkey and as low as 4.16% in China. This growing incidence correlates with an aging population in the U.S., where it is projected that around 20% of citizens will be aged 65 and older by 2024. This demographic is more susceptible to GERD due to higher rates of obesity, diabetes, and other chronic conditions, necessitating tailored therapeutic solutions to effectively address their specific needs.

Increasing public awareness surrounding GERD has also fueled demand for over-the-counter medications. A 2023 population-based survey revealed that 40% of U.S. citizens reported experiencing GERD symptoms at some point, with 33% experiencing symptoms in the past week. This heightened awareness has spurred consumers to seek immediate relief through antacids and proton pump inhibitors, a trend expected to persist into 2024 due to ongoing awareness campaigns. As more individuals recognize the available treatment options, the market for GERD therapeutics is poised for significant growth.

To learn more about this report, Download Free Sample Report

Government initiatives also play a critical role in promoting the GERD therapeutics market. In 2023, the World Health Organization launched a global initiative aimed at reducing gastrointestinal diseases through increased research funding and public health campaigns. Various national health departments are now implementing educational programs to raise awareness of GERD risk factors and encourage healthier lifestyles. It is anticipated that several countries will enhance their healthcare policies to support early diagnosis and treatment of GERD, further facilitating market growth in response to increasing healthcare expenditures and awareness efforts.

Market Dynamics

The gastroesophageal reflux disease therapeutics market is driven by the increasing prevalence of reflux related disorders, growing awareness regarding gastrointestinal health, and rising demand for effective treatment options across both prescription and over the counter segments. Healthcare providers are placing greater emphasis on early diagnosis and appropriate disease management to reduce symptom burden and prevent complications associated with chronic reflux conditions. Continued utilization of proton pump inhibitors, histamine receptor antagonists, and emerging potassium competitive acid blockers is supporting market growth. A notable industry development highlights this trend. For instance, in May 2025, Phathom Pharmaceuticals advanced the commercialization of VOQUEZNA (vonoprazan), an FDA approved potassium competitive acid blocker for the treatment of erosive and non-erosive gastroesophageal reflux disease, supporting broader treatment options and strengthening competition within the GERD therapeutics market. At the same time, increasing focus on personalized treatment strategies and long term disease management is encouraging broader adoption of therapeutic interventions. However, generic competition, concerns regarding prolonged use of certain acid suppressing therapies, and reimbursement related challenges continue to influence market dynamics. Despite these factors, ongoing investment in therapeutic innovation and expanding access to gastroenterology care are expected to support sustained market development.

Analyst Perspective

The gastroesophageal reflux disease therapeutics market continues to be supported by the widespread use of proton pump inhibitors, which remain the primary treatment option across most patient populations. However, a considerable number of patients continue to experience persistent symptoms despite treatment, creating demand for additional therapeutic options. This has increased attention toward newer therapies, including potassium competitive acid blockers, which are expanding available treatment choices within the market. At the same time, the widespread availability of generic therapies continues to influence prescribing patterns and treatment adoption across many regions. Ongoing clinical development activities, increasing disease awareness, and improving access to gastroenterology services are further contributing to market development. As treatment options continue to expand, competition is expected to increase across both established and emerging therapeutic classes, supporting continued evolution of the gastroesophageal reflux disease therapeutics market.

Drug Type Insights

Based on drug type, the antacids segment led the market with the largest revenue share of 56.7% in 2025, fueled by the effectiveness of antacids in delivering rapid relief from heartburn and acid indigestion. As over-the-counter (OTC) medications, they are easily accessible, cost-effective, and favored for self-medication. Their rising popularity is fueled by increased GERD prevalence and lifestyle factors contributing to acid-related disorders.

H2 receptor blockers are projected to grow at the fastest CAGR of 2.2% over the forecast period due to the efficacy of these medications in reducing stomach acid production, offering longer-lasting relief compared to antacids. Their widespread availability as over-the-counter options enhances accessibility for consumers seeking treatment for mild to moderate GERD symptoms, further contributing to their increasing popularity.

Regional Insights

North America dominated the gastroesophageal reflux disease therapeutics market with the largest revenue share of 38.1% in 2025. Market growth in the region is propelled by lifestyle factors, including obesity and dietary habits. The robust healthcare infrastructure, substantial investments in research and development, and increased awareness of GERD symptoms collectively enhance the demand for effective therapeutic options in this sector.

To learn more about this report, Download Free Sample Report

U.S. Gastroesophageal Reflux Disease Therapeutics Market Trends

The gastroesophageal reflux disease therapeutics market in the U.S. held the largest share in the North America region in 2025. The demand for GERD therapeutics in the U.S. is further stimulated by enhanced public awareness campaigns, a rising trend toward self-medication, and the accessibility of advanced treatment options. These factors collectively contribute to the growing market for effective GERD management solutions.

Europe Gastroesophageal Reflux Disease Therapeutics Market Trends

Europe gastroesophageal reflux disease therapeutics market held substantial market share in 2025, owing to a marked increase in GERD prevalence attributed to lifestyle changes and dietary habits. Enhanced healthcare spending, continuous research initiatives, and public health campaigns aimed at elevating GERD awareness are driving demand for effective therapeutic interventions across European nations.

The gastroesophageal reflux disease therapeutics market in Germany is expected to grow rapidly over the forecast period, driven by a strong healthcare infrastructure and a high prevalence of GERD within its population. The nation benefits from advanced pharmaceutical research and development, coupled with rising public awareness of available treatment options, which collectively fuel demand for tailored, effective therapeutic solutions that meet patient needs.

Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Trends

Asia Pacific gastroesophageal reflux disease therapeutics market is expected to register the fastest CAGR of 5.1% over the forecast period. The region is witnessing swift urbanization, shifting dietary habits, and increasing obesity rates. Enhanced healthcare investments and growing awareness of GERD symptoms and treatment options are propelling market expansion, establishing it as a significant growth area within the global therapeutics landscape.

The gastroesophageal reflux disease therapeutics market in China dominated the Asia Pacific gastroesophageal reflux disease therapeutics market in 2024. There has been a substantial rise in GERD cases linked to lifestyle changes and dietary modifications among the population. The government’s emphasis on enhancing healthcare infrastructure and promoting awareness of GERD treatment options further accelerates market growth in this sector.

Key Gastroesophageal Reflux Disease Therapeutics Company Insights

Some key companies operating in the market include AstraZeneca; Eisai Co., Ltd.; GSK plc.; Takeda Pharmaceutical Company Limited; and Ironwood; among others. Key players are prioritizing innovative drug development and strategic partnerships. Companies are investing in research and development to improve therapeutic options, while awareness campaigns are driving consumer demand.

• Eisai Co., Ltd., with its proton pump inhibitor, Pariet (rabeprazole), target reflux esophagitis and non-erosive GERD. They are also developing Lemborexant, currently in Phase II trials, to improve treatment options.

• GSK plc provides a variety of medications for gastroesophageal reflux disease, including proton pump inhibitors and H2 receptor antagonists. The company emphasizes research and development to create innovative therapies that effectively alleviate GERD symptoms and enhance overall gastrointestinal health for patients.

Key Gastroesophageal Reflux Disease Therapeutics Companies:

The following key companies have been profiled for this study on the gastroesophageal reflux disease therapeutics market.

• AstraZeneca

• Eisai Co., Ltd.

• GSK plc

• Takeda Pharmaceutical Company Limited

• Ironwood

• Johnson & Johnson Services, Inc.

• SFJ Pharmaceuticals

• Sebela Pharmaceuticals

• Phathom Pharmaceuticals, Inc.

• Camber Pharmaceuticals, Inc.

Recent Developments

• In October 2024, Camber announced the successful launch of eight new generic products in Q3, enhancing its portfolio with high-quality, cost-effective alternatives to brand-name medications.

• In July 2024, Phathom Pharmaceuticals announced FDA approval for VOQUEZNA® (vonoprazan) 10 mg tablets, offering a new treatment for heartburn associated with Non-Erosive GERD, benefiting millions of affected adults.

• In July 2024, AstraZeneca announced an approximately USD 30 million investment to expand its Global Innovation and Technology Centre in Chennai, creating approximately 1,300 skilled positions by 2025.

• In June 2024, Takeda expanded its partnership with Partners In Health to enhance health equity in Massachusetts, aiming to dismantle systemic barriers and strengthen local health workforce capacity.

Global Gastroesophageal Reflux Disease Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global gastroesophageal reflux disease therapeutics market report based on drug type and region:

To learn more about this report, Download Free Sample Report

• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Antacids

  • H2 Receptor Blockers

  • Proton Pump Inhibitors (PPIs)

  • Pro-kinetic Agents

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The gastroesophageal reflux disease therapeutics market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each gastroesophageal reflux disease therapeutics segment quantified using the revenue-capture definitions in the table below.

Estimation Model

The market size of the Gastroesophageal Reflux Disease (GERD) Therapeutics Market is estimated through a combination of secondary research, primary research, and data triangulation techniques. The study begins with extensive secondary research, including the analysis of annual reports, investor presentations, company financial statements, regulatory publications, clinical trial databases, healthcare journals, and data from organizations such as the World Health Organization (WHO), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and gastroenterology associations. This research helps identify the prevalence of GERD, treatment adoption patterns, therapeutic advancements, pricing trends, and key market participants.

A bottom-up approach is employed by assessing revenues generated from GERD therapeutics, including proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, potassium-competitive acid blockers (P-CABs), and other emerging therapies across major manufacturers and geographic regions. Simultaneously, a top-down approach is conducted by evaluating overall gastrointestinal drug expenditures and determining the proportion attributable to GERD treatment based on disease prevalence, prescription volumes, and treatment rates.

Primary research is carried out through interviews with gastroenterologists, hospital pharmacists, pharmaceutical executives, distributors, healthcare providers, and industry experts to validate market estimates, treatment trends, and future demand outlook. Market segmentation is analyzed by drug class, route of administration, distribution channel, and region. Finally, data triangulation and forecast modeling are applied to reconcile findings from multiple sources and generate accurate market size estimates and growth projections for the GERD Therapeutics Market.

Delivered Customizations

This report has been delivered with the following In-depth customizations